cT1 as a Monitoring Tool in Metabolic Dysfunction Associated Steatotic Liver Disease

Description

Supported by:  Perspectum

In this session we will introduce cT1, a well-established biomarker in liver disease derived from MRI technology. cT1 has played a pivotal role in numerous clinical trials focused on Steatotic Liver Disease, proving its effectiveness in patient selection for enrolment and real-time response monitoring. We will showcase cT1's performance as a marker of response to interventions and explore its practical applications in tailoring individualized patient management strategies.

Presenters: 

Dr. Craig Lammert MD

Dr. Naim Alkhouri MD, FAASLD, Hepatologist